Because Semaglutide is Linked to NAION, Wegovy and Ozempic Drug Injury Cases Have Been Filed In the US

(Posted by Tom Lamb at Drug Injury Watch)

Here is what you need to know:

• Semaglutide is linked to NAION, short for non-arteritic anterior ischemic optic neuropathy.
• Wegovy and Ozempic are drugs with semaglutide as their active ingredient.
• NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
• There are no proven medical treatments for NAION at present.
• The Wegovy and Ozempic drug labels do not warn about NAION as an eye-related side effect.

For more than a year now, we have been looking into possible drug injury lawsuits for patients who have been diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) while using Wegovy and Ozempic — as well as Rybelsus, which is another semaglutide-containing drug from Novo Nordisk.

Despite numerous medical studies suggesting that semaglutide is linked to NAION, the current Wegovy and Ozempic drug labels in the US do not have any warnings about eye-related side effects, such as non-arteritic anterior ischemic optic neuropathy (NAION) and vision loss.

These vision loss drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients diagnosed with NAION would be filed against Novo Nordisk for its failure to warn about any eye-related side effects in the current US drug label.

According to a November 21, 2025, Reuters news report, “Denmark compensates patients for vision loss linked to Novo Nordisk drugs“:

Four patients in Denmark, who experienced vision loss after using Novo Nordisk’s (NOVOb.CO) popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the Danish Patient Compensation association said on Friday.

The two drugs, which contain the active ingredient semaglutide, have been linked in very rare cases to a serious eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), the European Medicines Agency’s safety committee noted in June. The condition can cause permanent vision loss.

The Danish Patient Compensation association is an independent body that evaluates patient claims on behalf of the government in Denmark, where health authorities generally pay out medical compensation for a drug injury such as NAION.

More details were provided in this article, “Denmark Compensates Four Over Vision Loss Linked To Ozempic, Wegovy“, published November 21, 2025, by the Agence France Presse (AFP):

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and Ozempic are entitled to compensation, an independent body ruled Friday.

More than 40 people had sought reimbursement after they said they had developed a serious eye condition as a result of using one of the drugs, both made by Novo Nordisk, according to the Danish Patient Compensation association.

The condition — NAION (non-arteritic anterior ischemic optic neuropathy) — is a lack of blood supply to the optic nerve, which can lead to a loss of vision.

The association said that it had ruled on five cases so far, and found four people who merited compensation….

Last year, the Danish Medicines Agency asked a European medical watchdog to review a Danish study that showed a link between semaglutide — the active ingredient in Ozempic and Wegovy — and NAION.

In June, that watchdog — the PRAC (Pharmacovigilance Risk Assessment Committee) — concluded that NAION was a “very rare” side effect of semaglutide, affecting up to 1 in 10,000 users.

If you are interested in a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit seeking legal compensation for a NAION eye case, you can submit an Online Case Evaluation Form. It is free, confidential, and there is no obligation.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation – Free. Confidential. No Obligation.